Klose and colleagues show that the neuropeptide vasoactive intestinal peptide (VIP) acts on LGR5+ epithelial stem cells in the gut to restrain their proliferation and differentiation to secretory cell types. This VIP–VIPR1 interaction acts to limit type 2 immune responses.